Anakinra as first-line monotherapy for new-onset steroid-naïve sJIA patients.

The document discusses the use of anakinra as a first-line monotherapy for new-onset steroid-naïve systemic juvenile idiopathic arthritis (sJIA) patients. It highlights the effectiveness of anakinra in achieving inactive disease status and prolonged remission without the need for glucocorticoids. The text emphasizes the importance of early initiation of anakinra as monotherapy in newly diagnosed sJIA patients to improve treatment outcomes and prognosis. Additionally, it mentions the need for further studies to compare anakinra monotherapy with combined treatment in sJIA patients. [Extracted from the article]